Progress and challenges for malaria vaccines

Thomas L. Richie () and Allan Saul ()
Additional contact information
Thomas L. Richie: Malaria Program, Naval Medical Research Center
Allan Saul: Malaria Vaccine Development Unit, NIAID, National Institutes of Health, Twinbrook I

Nature, 2002, vol. 415, issue 6872, 694-701

Abstract: Abstract Malaria causes much physical and economic hardship in tropical regions, particularly in communities where medical care is rudimentary. Should a vaccine be developed, it is the residents of these areas that stand to benefit the most. But the vaccine, which has been promised to be 'just round the corner' for many years, remains elusive. It is important to ask why this is so, when effective vaccines exist for many other infectious diseases. What are the reasons for the slow rate of progress, and what has been learned from the first clinical trials of candidate malaria vaccines? What are the remaining challenges, and what strategies can be pursued to address them?

Date: 2002
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/415694a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:415:y:2002:i:6872:d:10.1038_415694a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/415694a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().